A single institute retrospective trial of concurrent chemotherapy with SIR-Spheres® versus SIR-Spheres® alone in chemotherapyresistant colorectal cancer liver metastases

May Cho, Jonathan Kessler, John J. Park, Aram Lee, Jun Gong, Gagandeep Singh, Yi Jen Chen, Philip H.G. Ituarte, Marwan Fakih

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The use of selective internal radiation therapy with yttrium 90 resin microspheres (SIRSpheres ®) in chemotherapy-resistant colorectal cancer liver metastases has been associated with favorable progression-free survival (PFS) and overall survival when given alone or concurrently with chemotherapy. We conducted a single institute retrospective trial to explore the potential impact of SIR-Spheres® with concurrent chemotherapy vs. SIR-Spheres® alone on liver PFS in patients with colorectal liver metastases (CRLM). Methods: Patients with 5-fluorouracil-refractory CRLM treated with SIR-Spheres® between 2009 and 2014 were identified. Patients were excluded if they received any chemotherapy/targeted regimen following radioembolization on which they did not previously progress. This strategy was adopted to minimize the impact of post-SIR-Spheres® systemic therapy bias on PFS. Results: Twenty-seven patients satisfied inclusion criteria and were included in this analysis. Patients' demographics were similar between the two treatment arms, except for the median number of prior therapies. No associated ≥ grade 3 toxicities were noted. Liver disease control rates were 84% and 14% on the SIR-Spheres® plus chemotherapy arms and SIR-Spheres® alone arms, respectively (P=0.001). Median PFS in the liver was 176 days in the SIR-Spheres® plus chemotherapy group vs. 91 days in the SIR-Sphere® alone group (P=0.0009). Median overall survival was 212 days in the SIR-Spheres® plus chemotherapy group vs. 154 days in the SIR-Spheres® alone group (P=0.1023). Conclusions: In patients with 5-fluorouracil-refractory disease, SIR-Spheres® plus chemotherapy is associated with an increased liver disease control rate and a prolonged liver PFS in comparison with SIRSpheres ® alone.

Original languageEnglish (US)
Pages (from-to)608-613
Number of pages6
JournalJournal of Gastrointestinal Oncology
Volume8
Issue number4
DOIs
StatePublished - Aug 1 2017
Externally publishedYes

Fingerprint

Liver Neoplasms
Colorectal Neoplasms
Neoplasm Metastasis
Drug Therapy
Disease-Free Survival
Liver
Fluorouracil
Liver Diseases
Yttrium
Survival
Microspheres
Radiotherapy
Therapeutics
Demography

Keywords

  • Colorectal liver metastases
  • Concurrent chemotherapy
  • SIR-Spheres®

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

A single institute retrospective trial of concurrent chemotherapy with SIR-Spheres® versus SIR-Spheres® alone in chemotherapyresistant colorectal cancer liver metastases. / Cho, May; Kessler, Jonathan; Park, John J.; Lee, Aram; Gong, Jun; Singh, Gagandeep; Chen, Yi Jen; Ituarte, Philip H.G.; Fakih, Marwan.

In: Journal of Gastrointestinal Oncology, Vol. 8, No. 4, 01.08.2017, p. 608-613.

Research output: Contribution to journalArticle

Cho, May ; Kessler, Jonathan ; Park, John J. ; Lee, Aram ; Gong, Jun ; Singh, Gagandeep ; Chen, Yi Jen ; Ituarte, Philip H.G. ; Fakih, Marwan. / A single institute retrospective trial of concurrent chemotherapy with SIR-Spheres® versus SIR-Spheres® alone in chemotherapyresistant colorectal cancer liver metastases. In: Journal of Gastrointestinal Oncology. 2017 ; Vol. 8, No. 4. pp. 608-613.
@article{53204d15de2344c6babd98722a023a7e,
title = "A single institute retrospective trial of concurrent chemotherapy with SIR-Spheres{\circledR} versus SIR-Spheres{\circledR} alone in chemotherapyresistant colorectal cancer liver metastases",
abstract = "Background: The use of selective internal radiation therapy with yttrium 90 resin microspheres (SIRSpheres {\circledR}) in chemotherapy-resistant colorectal cancer liver metastases has been associated with favorable progression-free survival (PFS) and overall survival when given alone or concurrently with chemotherapy. We conducted a single institute retrospective trial to explore the potential impact of SIR-Spheres{\circledR} with concurrent chemotherapy vs. SIR-Spheres{\circledR} alone on liver PFS in patients with colorectal liver metastases (CRLM). Methods: Patients with 5-fluorouracil-refractory CRLM treated with SIR-Spheres{\circledR} between 2009 and 2014 were identified. Patients were excluded if they received any chemotherapy/targeted regimen following radioembolization on which they did not previously progress. This strategy was adopted to minimize the impact of post-SIR-Spheres{\circledR} systemic therapy bias on PFS. Results: Twenty-seven patients satisfied inclusion criteria and were included in this analysis. Patients' demographics were similar between the two treatment arms, except for the median number of prior therapies. No associated ≥ grade 3 toxicities were noted. Liver disease control rates were 84{\%} and 14{\%} on the SIR-Spheres{\circledR} plus chemotherapy arms and SIR-Spheres{\circledR} alone arms, respectively (P=0.001). Median PFS in the liver was 176 days in the SIR-Spheres{\circledR} plus chemotherapy group vs. 91 days in the SIR-Sphere{\circledR} alone group (P=0.0009). Median overall survival was 212 days in the SIR-Spheres{\circledR} plus chemotherapy group vs. 154 days in the SIR-Spheres{\circledR} alone group (P=0.1023). Conclusions: In patients with 5-fluorouracil-refractory disease, SIR-Spheres{\circledR} plus chemotherapy is associated with an increased liver disease control rate and a prolonged liver PFS in comparison with SIRSpheres {\circledR} alone.",
keywords = "Colorectal liver metastases, Concurrent chemotherapy, SIR-Spheres{\circledR}",
author = "May Cho and Jonathan Kessler and Park, {John J.} and Aram Lee and Jun Gong and Gagandeep Singh and Chen, {Yi Jen} and Ituarte, {Philip H.G.} and Marwan Fakih",
year = "2017",
month = "8",
day = "1",
doi = "10.21037/jgo.2017.03.15",
language = "English (US)",
volume = "8",
pages = "608--613",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "4",

}

TY - JOUR

T1 - A single institute retrospective trial of concurrent chemotherapy with SIR-Spheres® versus SIR-Spheres® alone in chemotherapyresistant colorectal cancer liver metastases

AU - Cho, May

AU - Kessler, Jonathan

AU - Park, John J.

AU - Lee, Aram

AU - Gong, Jun

AU - Singh, Gagandeep

AU - Chen, Yi Jen

AU - Ituarte, Philip H.G.

AU - Fakih, Marwan

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Background: The use of selective internal radiation therapy with yttrium 90 resin microspheres (SIRSpheres ®) in chemotherapy-resistant colorectal cancer liver metastases has been associated with favorable progression-free survival (PFS) and overall survival when given alone or concurrently with chemotherapy. We conducted a single institute retrospective trial to explore the potential impact of SIR-Spheres® with concurrent chemotherapy vs. SIR-Spheres® alone on liver PFS in patients with colorectal liver metastases (CRLM). Methods: Patients with 5-fluorouracil-refractory CRLM treated with SIR-Spheres® between 2009 and 2014 were identified. Patients were excluded if they received any chemotherapy/targeted regimen following radioembolization on which they did not previously progress. This strategy was adopted to minimize the impact of post-SIR-Spheres® systemic therapy bias on PFS. Results: Twenty-seven patients satisfied inclusion criteria and were included in this analysis. Patients' demographics were similar between the two treatment arms, except for the median number of prior therapies. No associated ≥ grade 3 toxicities were noted. Liver disease control rates were 84% and 14% on the SIR-Spheres® plus chemotherapy arms and SIR-Spheres® alone arms, respectively (P=0.001). Median PFS in the liver was 176 days in the SIR-Spheres® plus chemotherapy group vs. 91 days in the SIR-Sphere® alone group (P=0.0009). Median overall survival was 212 days in the SIR-Spheres® plus chemotherapy group vs. 154 days in the SIR-Spheres® alone group (P=0.1023). Conclusions: In patients with 5-fluorouracil-refractory disease, SIR-Spheres® plus chemotherapy is associated with an increased liver disease control rate and a prolonged liver PFS in comparison with SIRSpheres ® alone.

AB - Background: The use of selective internal radiation therapy with yttrium 90 resin microspheres (SIRSpheres ®) in chemotherapy-resistant colorectal cancer liver metastases has been associated with favorable progression-free survival (PFS) and overall survival when given alone or concurrently with chemotherapy. We conducted a single institute retrospective trial to explore the potential impact of SIR-Spheres® with concurrent chemotherapy vs. SIR-Spheres® alone on liver PFS in patients with colorectal liver metastases (CRLM). Methods: Patients with 5-fluorouracil-refractory CRLM treated with SIR-Spheres® between 2009 and 2014 were identified. Patients were excluded if they received any chemotherapy/targeted regimen following radioembolization on which they did not previously progress. This strategy was adopted to minimize the impact of post-SIR-Spheres® systemic therapy bias on PFS. Results: Twenty-seven patients satisfied inclusion criteria and were included in this analysis. Patients' demographics were similar between the two treatment arms, except for the median number of prior therapies. No associated ≥ grade 3 toxicities were noted. Liver disease control rates were 84% and 14% on the SIR-Spheres® plus chemotherapy arms and SIR-Spheres® alone arms, respectively (P=0.001). Median PFS in the liver was 176 days in the SIR-Spheres® plus chemotherapy group vs. 91 days in the SIR-Sphere® alone group (P=0.0009). Median overall survival was 212 days in the SIR-Spheres® plus chemotherapy group vs. 154 days in the SIR-Spheres® alone group (P=0.1023). Conclusions: In patients with 5-fluorouracil-refractory disease, SIR-Spheres® plus chemotherapy is associated with an increased liver disease control rate and a prolonged liver PFS in comparison with SIRSpheres ® alone.

KW - Colorectal liver metastases

KW - Concurrent chemotherapy

KW - SIR-Spheres®

UR - http://www.scopus.com/inward/record.url?scp=85027315212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027315212&partnerID=8YFLogxK

U2 - 10.21037/jgo.2017.03.15

DO - 10.21037/jgo.2017.03.15

M3 - Article

AN - SCOPUS:85027315212

VL - 8

SP - 608

EP - 613

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 4

ER -